CompletedPhase 2NCT01420926
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
Studying Acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Gail J RobozAlliance for Clinical Trials in Oncology
- Intervention
- Bortezomib(drug)
- Enrollment
- 165 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2011 – 2021
Study locations (30)
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- Hartford Hospital, Hartford, Connecticut, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- AdventHealth Orlando, Orlando, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Harold Alfond Center for Cancer Care, Augusta, Maine, United States
- Eastern Maine Medical Center, Bangor, Maine, United States
- Christiana Care - Union Hospital, Elkton, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01420926 on ClinicalTrials.govOther trials for Acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07493538MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07075016Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPHASE1NCT06649227Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19University Hospital, Lille
- RECRUITINGNANCT07237230Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid LeukemiaDonghua Zhang
- RECRUITINGPHASE1, PHASE2NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Debiopharm International SA
- RECRUITINGNCT06899581Gut Health in Children With CancerGreat Ormond Street Hospital for Children NHS Foundation Trust
- RECRUITINGPHASE2NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China